La cadena de opciones muestra datos clave de las opciones de acciones de Catheter Precision a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Catheter Precision..

Catheter Precision (AMEX:VTAK) Bolsa, Cadena de Opciones

Catheter Precision, Inc. Common Stock

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Catheter Precision

Mercados

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BDRX

DECK

HNRG

IMMX

INEO

INTU

LITM

LTBR

MLGO

MNSO

OKLO

ROST

SGBX

SOBR

VTAK

Intuit sorprende al mercado con ingresos y BPA mejores de lo esperado. Revisa los mayores ganadores y perdedores del premercado.

Las acciones de Intuit (INTU) cotizan un 8% más alto; Aquí están 20 acciones que se mueven en el premercado

Urban Outfitters

ATCH

BTOG

DGLY

KDLY

LTRY

LUMN

MANU

NINE

NVTS

SEDG

SNOW

UPXI

URBN

VSTE

WHLR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Urban Outfitters sube tras superar expectativas de beneficios; otras acciones como Navitas y Snowflake también destacan en el premercado.

Acciones de Urban Outfitters (URBN) se disparan un 18%; Aquí están 20 acciones que se mueven en el premercado

CASY

Reuters Cites Hedge Fund Third Point Letter To Investors Saying Made New Investments In Rocket Companies And Informa PLC And Added To Position In Casey's General Stores In Q2

Typically, when a publicly traded enterprise loses 14% of equity value, it's a strong sign to avoid that name. However, an exception could be arguably made for cybersecurity giant Check Point Software Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>). Despite delivering an <a href="https://www.benzinga.com/quote/CHKP/earnings">earnings beat for the second quarter</a>, Check Point suffered an exodus of investors as they read between the lines. Still, it's very possible that the selloff in CHKP stock could be overdone.
In terms of headline numbers, Check Point posted earnings per share of $2.37. This figure landed at the midpoint of management's guidance but was 6.28% above analysts' estimated EPS of $2.36. In the year-ago quarter, the company posted earnings of $2.17 per share. On the top line, the cybersecurity giant rang up $665.2 million, above the midpoint guidance of $662 million. Analysts anticipated sales of $661.75 million.
However, investors had a dim view of the finer details. According to Check Point's second-quarter <a href="https://www.checkpoint.com/downloads/investor/CHKP-Q2-25-Preso.pdf?v=1.0">presentation</a>, billings landed at $642 million, representing only 4% growth from the year-ago period's tally of $620 million. In contrast, total revenues grew 6%. Since billings represent a leading indicator of future revenue, the market likely viewed this metric as a major red flag.
Another problem likely centered on the business forecast. Management decided to make no change regarding its fiscal year 2025 expectations despite the second-quarter earnings beat. Investors may have interpreted this silence as a lack of confidence regarding future expectations.
Still, not all hope may be lost. With the post-earnings implosion, you could make the argument that CHKP stock is more attractively priced. Such assertions are tricky because you would be assuming that the prior price represented the security's "true value" and that today's drop is somehow a deviation. From a lived experience perspective, though, we know that some stocks tend to overcorrect prior to reaching a relative equilibrium.
Now, what makes CHKP stock a more credible discount — rather than a wild presuppositional fallacy — is the underlying industry. For practically all intents and purposes, cybersecurity is permanently relevant. As other analysts have pointed out, it's <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44501515/cybersecurity-stocks-to-outperform-its-the-one-line-item-that-no-company-in-the-world-is-cutting-josh-brown">the one line item</a> that companies really can't afford to skimp out on due to the criticality of digital protection.
<h2 class="wp-block-heading">A Risky But Compelling Empirical Argument For CHKP Stock</h2>
Earlier, I mentioned that the concept of CHKP stock being discounted risks becoming a presuppositional fallacy. The reason isn't so much that the assessment itself is fallacious. Rather, it's more of a structural problem. Simply put, there's no objective way to define "true value" as opposed to "fake value" or some other financial pejorative.
It comes down to the harsh reality that stock prices and financial metrics such as earnings are continuous scalar signals. They merely represent the point at which a transaction took place. Even worse from an analyst's perspective, the signal is unbounded. Theoretically, CHKP stock could rise infinitely, which necessarily means that there's no objective mechanism to define when it has reached a "good price."
As far as I know, the only objective truth that has real analytical meaning is that, at the end of the day, the market is either a net buyer or net seller.
Let's take a look at the last 10 weeks of CHKP stock. Most people see an undulation of pricing activity. I see a sentiment voting record. During this period, the market voted to buy CHKP four times and sell six times. Overall, the security saw a downward trajectory. For brevity, we can label this sequence as 4-6-D.
Why the simple binary code? Because now, I can look back in the history of my dataset (which goes back to January 2019) to determine how many times on a rolling basis this sequence has flashed. This gives me an empirical basis to understand how the market responds to the 4-6-D sequence. As well, I can categorize the entire demand profile of CHKP stock, which would allow us to have a decision tree:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Ticker</td>
<td>L10 Category</td>
<td>Sample Size</td>
<td>Up Probability</td>
<td>Baseline Probability</td>
<td>Median Return if Up</td>
</tr>
<tr>
<td>CHKP</td>
<td>3-7-D</td>
<td>7</td>
<td>71.43%</td>
<td>58.60%</td>
<td>0.77%</td>
</tr>
<tr>
<td>CHKP</td>
<td>4-6-D</td>
<td>31</td>
<td>70.97%</td>
<td>58.60%</td>
<td>1.22%</td>
</tr>
<tr>
<td>CHKP</td>
<td>4-6-U</td>
<td>11</td>
<td>72.73%</td>
<td>58.60%</td>
<td>1.02%</td>
</tr>
<tr>
<td>CHKP</td>
<td>5-5-D</td>
<td>56</td>
<td>58.93%</td>
<td>58.60%</td>
<td>1.75%</td>
</tr>
<tr>
<td>CHKP</td>
<td>5-5-U</td>
<td>35</td>
<td>45.71%</td>
<td>58.60%</td>
<td>2.16%</td>
</tr>
<tr>
<td>CHKP</td>
<td>6-4-D</td>
<td>30</td>
<td>60.00%</td>
<td>58.60%</td>
<td>2.44%</td>
</tr>
<tr>
<td>CHKP</td>
<td>6-4-U</td>
<td>43</td>
<td>46.51%</td>
<td>58.60%</td>
<td>2.45%</td>
</tr>
<tr>
<td>CHKP</td>
<td>7-3-D</td>
<td>11</td>
<td>81.82%</td>
<td>58.60%</td>
<td>1.99%</td>
</tr>
<tr>
<td>CHKP</td>
<td>7-3-U</td>
<td>55</td>
<td>63.64%</td>
<td>58.60%</td>
<td>1.27%</td>
</tr>
<tr>
<td>CHKP</td>
<td>8-2-U</td>
<td>41</td>
<td>51.22%</td>
<td>58.60%</td>
<td>1.52%</td>
</tr>
</tbody>
</table>
</figure>
From the table above, the chance that a long position in CHKP stock will rise on any given week is 58.6%, a strong upward bias. This is effectively our null hypothesis, the expected performance assuming no mispricing. Our alternative hypothesis is that, because of the 4-6-D sequence flashing, the upside probability is now 70.97%.
Assuming that CHKP stock finds itself around $190 by the end of this week, it could work its way above $192. If the bulls manage to maintain control over the next two weeks, CHKP could rise above $194.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150841/CHKP-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-1007774" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150841/CHKP-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150841/CHKP-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150841/CHKP-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30150841/CHKP-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
The thing to remember, though, is that the current drop represents an extraordinary event. It's possible that, under the right conditions, a dead-cat bounce could be more pronounced than it would be following a "regular" bout of volatility.
<h2 class="wp-block-heading">An Intrepid Wager On Check Point Software</h2>
Those wanting to take a shot on the deep discount may consider the 190/195 bull call spread expiring Aug. 15. This transaction involves buying the $190 call and simultaneously selling the $195 call, for a net debit paid of $200 (the most that can be lost in the trade). Should CHKP stock rise through the short strike price ($195) at expiration, the maximum profit is $300, a payout of 150%.
The breakeven price for the above trade is at $192 at time of writing. Therefore, even though the median expected performance would put CHKP stock a bit shy of $195, it would still be forecasted to rise above the breakeven point. Of course, there's no guarantee that CHKP will move higher. However, the last time CHKP suffered such a massive drop — in October 2024 — it managed to move up about 3.2% week-to-week.
If CHKP stock could close at $190 or thereabouts, the $195 target by Aug. 15 does seem reasonable based on past analogs.
Of course, much hinges on the validity of the 4-6-D sequence. Running a one-tailed binomial test reveals a p-value of 0.0844, which means that there's an 8.44% chance that the implications of the sequence could materialize randomly as opposed to intentionally. This doesn't quite meet the 5% threshold of statistical significance. However, because of the stock market's open and entropic system, this is arguably an empirically intriguing signal.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46703716/pg-stock-post-earnings-blues-discounted-trade">Options Corner: Procter &amp; Gamble&#8217;s Tariff Blues Could Signal A Discounted Opportunity</a></li>
</ul>
Image: Shutterstock

Earnings Beats

Equities

Long Ideas

Options

CHKP

Options Corner: Check Point Software's Post-Earnings Implosion Opens Deep Value Opportunity For Speculators

eVTOL company Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is one of several in the sector that has seen its stock price soar with support from the current <a href="https://www.benzinga.com/markets/equities/25/06/45896929/trump-launches-aviation-overhaul-archer-joby-new-horizon-aerovironment-rally-as-us-targets-drone-evtol-supersonic-comeback">White House administration.</a>
Archer Aviation founder and CEO Adam Goldstein tells Benzinga why the White House&#8217;s support is so important for the sector.
White House Support: Goldstein highlighted a recent executive order from President Donald Trump that emphasizes <a href="https://www.benzinga.com/topic/evtol">drones and eVTOLs, </a>or electric vertical take-off and landing aircraft.
"This administration has had a big focus on rebuilding and modernizing air traffic control to make aviation not just safe but able to continue to grow and help move the economy along," Goldstein told Benzinga.
Goldstein said there has been bipartisan support for America to maintain its leadership in aviation, but the new White House administration accelerated that thinking.
The Archer Aviation CEO said there's evidence of the push to secure global aviation leadership in the One Big Beautiful Bill, with the White House putting their money where their mouth is.
"You've seen repeated steps by the administration to push the industry forward."
Read Also: <a href="https://www.benzinga.com/news/earnings/25/05/45361467/archer-aviation-reports-smaller-than-expected-loss-in-q1-company-says-uae-launch-remains-on-track-for-2025-shares-surge">Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains &#8216;On Track&#8217; For 2025, Shares Surge</a>
Defense Sector Primed for Growth: Along with the commercialization of passenger aircraft, Archer is also pushing forward plans in the defense sector.
Goldstein said there is a big focus on the defense side with the industry modernizing for modern-day conflicts.
"The defense opportunity I think may end up being larger than the civil opportunity in the first 10 years," Goldstein told Benzinga.
Goldstein said recent conflicts have shown that autonomous vehicles could be necessary to win. While many have seen small vehicles launched, Goldstein said big vehicles are coming.
The Archer Aviation CEO stated that defense vehicles in the eVTOL sector could play a key role in Western military strategies.
ACHR Price Action: Archer stock trades at $10.12 on Wednesday versus a 52-week trading range of $2.82 to $13.92. Archer stock is up 6.1% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45948701/archer-aviation-stock-rises-on-deal-to-deploy-midnight-aircraft-in-indonesia">Archer Aviation Stock Rises On Deal To Deploy Midnight Aircraft In Indonesia</a></li>
</ul>
Photo courtesy of Archer Aviation.

Politics

Exclusives

Interview

ACHR

EXCLUSIVE: Archer CEO Says Trump's eVTOL Push Is A Game-Changer

Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading lower on Wednesday.</a>
The firm&#8217;s sky-high rally hits a speed bump as revised yield outlook tempers investor expectations for 2025.
Goldman Sachs analyst Lizzie Dove reiterated the Buy rating on the company, lowering the price forecast from $364 to $361.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46693192/royal-caribbean-sails-past-wall-street-expectations-new-launches-performing-extremely-well" rel="noreferrer noopener"> Royal Caribbean Sails Past Wall Street Expectations, New Launches &#8216;Performing Extremely Well&#8217;</a>
After a 90% rally in Royal Caribbean shares over the past three months, expectations had risen sharply. However, the company's updated yield outlook didn't quite meet that elevated bar.
The downward revision of the high end of 2025 net yield guidance—from 4.6% to 4.0%—suggests that upside to earnings estimates may be more limited than many investors had hoped.
A shortening booking window—after already narrowing by one week for 2026 last quarter—isn't cause for alarm. The trend, she says, may prompt investors to pay close attention to Norwegian Cruise Line&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) update later in the week for more clarity on cruise trends.
The setup for 2026 net yield growth could surpass current expectations, Dove says. Contributions from ships like Star, Excel, and Legend, as well as the incremental benefit from the Beach Club and the potential tailwind of a more stable macroeconomic environment.
To account for pre-opening costs related to Costa Maya, the Beach Club, and Celebrity River, Dove has slightly lowered 2026 EBITDA and EPS forecasts.
The full-year guidance does not factor in any additional acceleration in close-in demand—a detail Dove anticipates will be conservative and may ultimately leave room for upward revisions.
Pending more evidence to support this potential, Dove has slightly adjusted the FY25 net yield estimate downward from +4.4% to +4.0%.
Price Action: RCL shares are trading lower by 1.01% to $331.06 at last check Wednesday,
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46688203/norfolk-southern-q2-earnings-revenue-eps-beat-estimates-company-flags-weaker-revenue-early-in-q3" target="_blank" rel="noreferrer noopener">Norfolk Southern Q2 Earnings: Revenue, EPS Beat Estimates, Company Flags ‘Weaker' Revenue Early In Q3</a></li>
</ul>
Image: Shutterstock

Travel

General

NCLH

Royal Caribbean's 2025 Upside May Be Limited, But 2026 Yield Growth Could Exceed Estimates

Macro Economic Events

Economics

Federal Reserve

Live On Fox News, Deputy U.S. Treasury Secretary Says There Is Scope For The Fed To Reduce Interest Rates

Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) shares are trading slightly lower Wednesday afternoon, despite the company posting impressive second-quarter results and an outlook that spurred a wave of analyst upgrades. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/RCL">need to know</a>.
What To Know: On Tuesday the cruise operator <a href="https://www.benzinga.com/pressreleases/25/07/n46682184/royal-caribbean-group-reports-second-quarter-results-and-increases-full-year-guidance">announced</a> strong second-quarter earnings, reporting an adjusted EPS of $4.38, sailing past Wall Street&#8217;s consensus estimate of $4.05. 
Revenue for the quarter also beat expectations, coming in at $4.54 billion. The company highlighted that booked load factors and rates are at an all-time high for all future sailings, driven by strong demand and resilient consumer spending.
Buoyed by the strong performance, Royal Caribbean raised its full-year adjusted EPS guidance to a range of $15.41 to $15.55. The company also increased its full-year adjusted EBITDA forecast to approximately $5.95 billion. Management credited the results to strong ticket pricing and robust onboard revenue.
In response to the report, Wall Street <a href="https://www.benzinga.com/quote/RCL/analyst-ratings">analysts</a> were overwhelmingly positive on Wednesday. A flurry of firms reiterated their Buy or Overweight ratings and increased their price targets.
Stifel raised its target to $420, Citigroup increased its target to $399, and JPMorgan lifted its target to $367. Despite the strong results and bullish analyst sentiment, the stock&#8217;s modest pullback may suggest a sell-the-news reaction or minor profit-taking by investors after the stock&#8217;s 111% run higher over the past year.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings, Royal Caribbean exhibits extremely strong momentum with a score of 93.86 out of 100. The company also receives a high score for growth at 77.30, reflecting its solid financial expansion. 
Conversely, its value score is more moderate at 47.28, suggesting the stock may not be considered undervalued based on current metrics. Reinforcing the high momentum score, the data also shows a positive price trend across short, medium, and long-term timeframes.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RCL shares are trading lower by 1.25% to $330.25 Wednesday afternoon. The stock has a 52-week high of $355.91 and a 52-week low of $130.08.
Read Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46733603/fed-holds-trump-powell-waller-bowman-interest-rates">Fed Skips Rate Cut Again—But Reveals Something We Haven&#8217;t Seen Since 1993</a>
<h2 class="wp-block-heading">How To Buy RCL Stock</h2>
By now you're likely curious about how to participate in the market for Royal Caribbean &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Royal Caribbean, which is trading at $332.15 as of publishing time, $100 would buy you 0.3 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

What's Going On With Royal Caribbean Cruises (RCL) Stock?

Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) shares are trading higher Wednesday after UBS upgraded the stock from a Neutral rating to a Buy rating and raised its price target from $7.50 to $11.
What To Know: The analyst cited three key reasons for upgrading the stock. First, the analyst sees room for upside in Peloton's fiscal year 2026 EBITDA, supported by revenue growth and ongoing cost cuts.
Next, the analyst notes improving trends in Peloton's underlying performance metrics. Lastly, the analyst views the stock as undervalued, noting it's trading at around 6 to 7 times EBITDA as cash flow starts to improve.
The consensus price target for Peloton is $10.60, with the lowest price target at $4.00 and the highest price target at $55.00.
How To Buy Peloton Stock
By now you're likely curious about how to participate in the market for Peloton &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Peloton, which is trading at $7.39 as of publishing time, $100 would buy you 13.53 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/insights/options/24/04/38410617/lucid-grs-options-frenzy-what-you-need-to-know">Lucid Gr&#8217;s Options Frenzy: What You Need to Know</a>
PTON Price Action: At the time of writing, Peloton stock is trading 17.2% higher at $7.24, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Image via Shutterstock

PTON

Peloton Stock Is Rising Higher Wednesday: What's Going On?

SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) saw its stock trading lower on Wednesday, despite Wall Street analysts reiterating their ratings after the company reported stronger-than-expected second-quarter financial results on Tuesday.
The fintech firm surpassed revenue and earnings estimates, driven by robust growth in its loan platform business and a significant increase in members and products, leading to Needham raising its price target on the stock.
SoFi reported second-quarter revenue of $858.23 million, beating analyst estimates of $801.49 million. Total revenue was up 44% as fee-based revenue climbed 72%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45081468/sofi-stock-pops-as-revenue-soars-and-ceo-teases-crypto-comeback" rel="noreferrer noopener">SoFi Stock Pops As Revenue Soars And CEO Teases Crypto Comeback</a>
Members grew 34% to 11.7 million and products increased 34% year-over-year to 17.1 million. SoFi originated&nbsp;$8.8 billion&nbsp;in loans during the quarter.
SoFi raised its full-year 2025 revenue outlook from a range of $3.24 billion to $3.31 billion to a new target of approximately $3.38 billion versus estimates of $3.27 billion.
In response to the strong results, Needham analyst Kyle Peterson reiterated a Buy rating on SoFi and increased his price forecast from $20 to $25. Conversely, Citizens JMP Securities analyst Devin Ryan maintained a Market Perform rating.
<h2 class="wp-block-heading">Needham&#8217;s Take</h2>
Peterson praised SoFi&#8217;s second-quarter results, highlighting that revenue and earnings significantly exceeded expectations and Street estimates. The outperformance was driven primarily by strong growth in SoFi&#8217;s loan platform business, which continues to benefit from resilient demand in private credit.
SoFi reported GAAP revenue of $854.9 million (+46% Y/Y), beating the analyst&#8217;s $805.5 million estimate and the $814.6 million consensus. Adjusted revenue of $858.2 million also exceeded forecasts.
GAAP EPS reached 8 cents, topping the analyst&#8217;s 6 cents estimate and consensus. EBITDA reached $249.1 million, well above the projected $207.5 million, thanks to revenue strength and improved operating leverage. Although net interest margin (NIM) declined slightly to 5.86% (versus 5.95% estimated), this was attributed to balance sheet mix shifts.
Following earnings, SoFi raised its fiscal 2025 guidance, now expecting net revenue of ~$3.375 billion (prior: $3.235 billion–$3.310 billion), EBITDA of ~$960 million (prior: $875 million–$895 million), and EPS of 31 cents (prior: 27 cents–28 cents).
Shortly after the report, SoFi completed a $1.5 billion secondary common stock offering at $20.85 per share, which Peterson viewed as opportunistically timed. This capital raise is expected to boost total risk-based capital by ~440 basis points, bringing it to an estimated 18.8%, a level the analyst sees as healthy given SoFi&#8217;s asset mix and growth profile. The analyst noted this improved capital position enhances SoFi&#8217;s appeal to institutional investors.
Citing stronger fundamentals and improved financial flexibility, Peterson raised his fiscal 2025 and 2026 EPS estimates.
The valuation is based on a sum-of-the-parts model that assigns $18 per share to the lending segment (at 2.5 times expected TBV) and $7 per share to the technology, financial services, and fee-based businesses, valued at ~7 times fiscal 2026 estimated revenue.
This valuation reflects the firm&#8217;s view of SoFi as a high-growth FinTech with a compelling long-term outlook. Peterson projected fiscal 2025 revenue of $3.38 billion and GAAP EPS of 31 cents.
<h2 class="wp-block-heading">Citizens JMP Securities&#8217; Perspective</h2>
Ryan described SoFi&#8217;s second-quarter fiscal 2025 as another standout quarter. Revenue and earnings were well above expectations, driven by exceptional loan platform performance.
Lending volumes remained strong, with $8.8 billion in originations (up 64% Y/Y), and personal loan originations hitting a record $4.5 billion. The analyst noted improving conditions for student and home loans, driven by waning federal support and expectations of falling interest rates, alongside SoFi&#8217;s more sophisticated go-to-market strategies.
The loan platform business (LPB) continues to gain traction, growing volume by over 50% quarter-over-quarter to $2.4 billion. Ryan highlighted LPB as a valuation-enhancing growth engine, with ample capacity and potential expansion into new loan categories.
In the technology segment, SoFi generated $33 million in contribution profit at a 30% margin, and management reiterated its outlook for low double-digit to teens revenue growth in 2025. SoFi expects 10 new clients to generate revenue in the first quarter of 2026, up from zero in the first quarter of 2025, pointing to future momentum.
The analyst also flagged early integration of blockchain and AI. SoFi discussed automating international peer-to-peer money transfers via blockchain, re-launching crypto investing, and exploring asset tokenization and treasury-linked stablecoin revenue.
On the AI side, the firm launched Cash Coach to help users optimize cash, with broader AI-enabled financial guidance expected to deepen customer engagement and asset consolidation over time.
Following strong results, SoFi raised full-year 2025 guidance. Although Ryan had recently downgraded the stock to Market Perform from Market Outperform (citing valuation concerns after a strong run), he acknowledged the quarter was even better than expected.
The analyst remains constructive on SoFi&#8217;s long-term optionality, particularly around blockchain, AI, and potential M&amp;A, but sees the risk and reward as balanced at current valuation levels in the low-to-mid $20s.
Their long-term model assumes revenues could triple by 2030, EBITDA margins could expand into the mid-30% range, and EPS could grow to ~$1.75+, supporting a fair value in the mid-$20 range when applying a 25 times multiple and a 13% discount rate.
Ryan projected fiscal 2025 revenue of $3.32 billion and adjusted EPS of 28 cents.
Price Action: SOFI stock is trading lower by 3.37% to $21.67 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46722008/garmin-stock-climbs-after-strong-q2-beat-fitness-and-outdoor-sales-surge-mylaps-acquisition" target="_blank" rel="noreferrer noopener">Garmin Stock Climbs After Strong Q2 Beat, Fitness And Outdoor Sales Surge, MYLAPS Acquisition</a></li>
</ul>
Image via Shutterstock

Price Target

Reiteration

Analyst Ratings

SOFI

SoFi's Loan Platform Shines In Q2, Driving Profitability And Growth

A woman from Raleigh, North Carolina, called into &#8220;<a href="https://www.youtube.com/watch?v=L1E2hq8-BsA">The Ramsey Show</a>&#8221; recently with a jaw-dropping financial dilemma.&nbsp;
Allie, who has been with her boyfriend for over a decade, recently learned he secretly racked up $80,000 in credit card debt. Now, he wants her to co-sign a $100,000 home equity line of credit on a house she doesn't even own.
<h2 class="wp-block-heading">He Took Care Of Her After A Tragedy, Now She's Paying All The Bills</h2>
Allie said she only discovered the debt when her boyfriend hit a financial wall. "He hit the end of the rope," she told co-hosts George Kamel and Jade Warshaw. That's when she learned he had <a href="https://www.benzinga.com/personal-finance/management/25/07/46604888/keep-your-utilization-rates-low-humphrey-yangs-top-tip-for-a-better-credit-score">maxed out every credit card</a>. He also still owes $40,000 in student loans.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a></li>
</ul>
His spending problem? Classic cars. Allie explained that he runs a restoration shop but is terrible at managing the business side. "He sees a car he wants, he gets it. He cycles through like three or four sports cars a year," she said.
Despite living with him for the last two years, her name isn&#8217;t on the mortgage. He recently asked her to co-sign a $100,000 home equity line of credit, or HELOC, so he could <a href="https://www.benzinga.com/money/heloc-to-pay-off-credit-card-debt">pay off the credit card debt</a>. Allie immediately knew that was a bad idea. "If he takes one of those sports cars and wraps her around a telephone pole, I&#8217;m stuck with his debt for the rest of my life," she said.&nbsp;
Allie admitted she briefly considered helping because of what he did for her in the past. After a devastating car accident left her with spinal injuries and a traumatic brain injury, Allie lost her house, car, job and life savings. Her health insurance company sued her to recover the $500,000 they had spent on her care. With nowhere else to go, she moved in with her boyfriend, who helped her recover.
But now, she's the one carrying the financial burden. "I&#8217;m currently paying all of our bills," she said. "Because he has nothing to pay them with."
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
<h2 class="wp-block-heading">Not Married, No Ring, No Security</h2>
Kamel and Warshaw were straightforward: she should not feel guilty or obligated to co-sign anything. "If somebody does something out of an act of generosity, they&#8217;re not looking to be paid back," Warshaw said.
They also pointed out how financially risky her situation has become. "You're paying his bills and you're broke," Kamel told her. "You&#8217;re not really gaining as much as you think."
Allie revealed she now earns about $35,000 a year, down from $70,000 before her injuries. Her health limitations keep her from taking more physically demanding jobs. And she said she feels trapped because she doesn't make enough to afford a place of her own.
Still, she admitted that if she had more money, she would leave the relationship.&nbsp;
Kamel and Warshaw encouraged her to keep searching for a rental or roommate situation. "There's a bunch of great girls out there who would love a great roommate like Allie who can pay her fair share," Kamel said. "He has chosen his obsession over you."
Read Next:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>
Image: Shutterstock

Personal Finance

Dave Ramsey Caller Discovers Her Boyfriend Hid $80,000 In Credit Card Debt. Now He's Asking Her To Co-Sign A $100,000 Loan On His Home

<a href="https://www.axios.com/2025/07/30/amazon-prices-trump-tariffs-senator-letter" title="https://www.axios.com/2025/07/30/amazon-prices-trump-tariffs-senator-letter">https://www.axios.com/2025/07/30/amazon-prices-trump-tariffs-senator-letter</a>

AMZN

Reported Earlier: 'Exclusive: Senate Dem Presses Amazon On Price Hikes Amid Tariffs' - Axios

WIIM

BITF

BTBT

BTCM

BTCS

BTDR

CIFR

CLSK

CNCK

MARA

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MSTR

RIOT

WULF

Shares of crypto-related companies are trading lower after Fed Chair Powell left rates unchanged. Fed Chair Powell mentioned that inflation is still above target.

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">metastatic colorectal cancer (mCRC)</a>.
Patients were randomized to one of six arms, including 20mg of onvansertib plus SoC, 30mg of onvansertib plus SoC, or SoC alone.
The overall objective response rate (ORR) was 59% on the high dose and 50% in the 20 mg dose, compared to a 43% response <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46704927/cardiff-oncology-announces-positive-data-from-ongoing-randomized-phase-2-first-line-ras-mutated-mc" rel="noreferrer noopener">rate in the control arm</a>.
After removing the ORRs at 6 months, the confirmed ORRs for the high-dose, low-dose, and control arms were 49%, 42%, and 30%, respectively.
<h2 class="wp-block-heading">Onvansertib Shows Promise With High Response Rates</h2>
For comparison, December 2024 data showed an ORR of 57% in all onvansertib patients, with 50% in the 20mg dose of onvansertib + SoC arm and 64% in the 30mg dose of onvansertib + SoC arm, compared to <a target="_blank" href="https://www.benzinga.com/24/12/42416310/whats-going-on-with-cardiff-oncology-stock-on-tuesday" rel="noreferrer noopener">33% in the SoC alone arm</a>.
Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses in patients receiving the 30mg dose of onvansertib combined with the SoC compared to the control arm and the 20mg dose of onvansertib arm.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46053581/exelixis-targets-5-billion-in-sales-with-promising-data-in-key-colorectal-cancer-drug-trial-stock-soars" rel="noreferrer noopener">Exelixis&#8217; Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars</a>
Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the progression-free Survival (PFS) curves compared to the control arm at a median follow-up time of 6 months.
While the median PFS has not been reached, a dose-dependent effect was observed in favor of the 30mg onvansertib dose.
The safety analysis was conducted for the 104 patients dosed in the trial. Onvansertib, in combination with chemotherapy and bevacizumab, was well-tolerated, and no major or unexpected toxicities were observed.
<h2 class="wp-block-heading">Can This Drug Change Colorectal Cancer Outcomes?</h2>
Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event associated with onvansertib.
Update on first-line mCRC program expected by the first quarter of 2026.
William Blair believes the current data on onvansertib justifies further investment, including moving forward with a Phase 3 trial.
The overall data shows that onvansertib is clearly effective, which analyst Andy Hsieh says weakens the bearish argument against the stock.
The key question is whether the ORR improvement will result in a meaningful gain in PFS, the main measure needed for approval.
<h2 class="wp-block-heading">How Dose Variations Impact Patient Survival Rates</h2>
Looking at past data, even a modest improvement in response rates—like the 11% increase seen in the Phase 3 TRIBE study—can result in a successful outcome in key trials, especially if it also boosts PFS.
In the Phase 3 BREAKWATER study for BRAF-mutated colorectal cancer, a 20% jump in response rate led to meaningful gains in PFS and overall survival.
Analyst Hsieh writes that the current valuation reflects considerable skepticism regarding the compound's clinical profile, which William Blair disagrees with.
William Blair holds a bullish view that onvansertib could potentially disrupt the RAS-mutated frontline mCRC treatment paradigm. <a target="_blank" href="https://www.benzinga.com/quote/CRDF/analyst-ratings" rel="noreferrer noopener">Reiterates Outperform rating</a>.
CRDF Price Action: Cardiff Oncology shares were down 19.94% at $2.65 at the time of publication on Wednesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46731635/american-electric-power-lifts-annual-gaap-outlook-to-announce-70-billion-capital-plan" target="_blank" rel="noreferrer noopener">American Electric Power Lifts Annual GAAP Outlook, To Announce $70 Billion Capital Plan</a></li>
</ul>
Photo: jittawit21/Shutterstock

Analyst Color

Biotech

Health Care

CRDF

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Global

Reuters Cites Statement Saying Brazil's Trade Panel Decides To Bring Forward Tariff Increase Schedule For Electric, Hybrid Vehicles; 35% Tariff On Electric, Hybrid Vehicles To Start On Jan, 2027 Vs July, 2028 Previously

<a href="https://www.bloomberg.com/news/articles/2025-07-30/us-hits-iran-oil-trading-network-in-sanctions-crackdown?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-07-30/us-hits-iran-oil-trading-network-in-sanctions-crackdown?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-30/us-hits-iran-oil-trading-network-in-sanctions-crackdown?srnd=homepage-americas</a>

Econ #s

'US Hits Iran Oil-Trading Network in Sweeping Sanctions Crackdown' - Bloomberg News

Polaris Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/PII/earnings">financial results on Tuesday</a>.
Polaris posted adjusted earnings of 40 cents per share, compared to market estimates of a loss of 4 cents per share. The company's quarterly sales came in at $1.852 billion beating expectations of $1.720 billion.
Polaris said it sees third-quarter sales of $1.600 billion to $1.800 billion, versus estimates of $1.671 billion.
Polaris shares gained 7.8% to trade at $53.32 on Wednesday.
These analysts made changes to their price targets on Polaris following earnings announcement.
<ul class="wp-block-list">
<li>Baird analyst Craig Kennison maintained Polaris with a Neutral and raised the price target from $46 to $55.</li>
<li>RBC Capital analyst Sabahat Khan maintained the stock with a Sector Perform and raised the price target from $34 to $56.</li>
<li>MO Capital analyst Tristan Thomas-Martin maintained Polaris with a Market Perform and raised the price target from $33 to $52.</li>
</ul>
Considering buying PII stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PII/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="565" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-1024x565.png" alt="" class="wp-image-1007799" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-1024x565.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30152021/image-490.png 1146w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>

Earnings

Polaris Analysts Boost Their Forecasts After Better-Than-Expected Q2 Earnings

Marvell Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">traded</a> higher Wednesday as the AI boom drives major tech companies to accelerate chip upgrades to meet surging global demand and strengthen their competitive positions.
The semiconductor firm, which provides chip design and services across data centers, enterprise networks, consumer tech, telecom infrastructure, and automotive, is benefiting from the renewed momentum.
Rebellions, a South Korea-based AI semiconductor company, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46686169/rebellions-announces-collaboration-with-marvell-to-deliver-custom-ai-infrastructure-for-sovereign-" rel="noreferrer noopener">has partnered with</a> Marvell to develop high-performance, energy-efficient AI systems designed explicitly for sovereign-backed and regionally focused AI initiatives across Asia-Pacific and the Middle East.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46492462/marvell-reshuffles-leadership-as-it-looks-to-reignite-momentum-rebuild-investor-confidence" rel="noreferrer noopener">Marvell Reshuffles Leadership As It Looks To Reignite Momentum, Rebuild Investor Confidence (CORRECTED)</a>
Through this collaboration, Rebellions will design custom AI accelerators using Marvell's advanced silicon platform, which includes cutting-edge packaging, high-speed SerDes, and die-to-die interconnect technology.
The partnership aims to deliver tightly integrated, rack-scale AI inference systems that meet the growing demand for scalable, efficient, and sovereign-controlled AI infrastructure—marking a strategic shift from traditional GPU-based architectures to specialized ASIC-driven solutions tailored for national competitiveness.
Marvell stock has plunged over 25% year-to-date, lagging behind the NASDAQ Composite Index's 10% gains, as concerns about the Trump administration's tariff policy and macroeconomic uncertainties weigh on the stock.
<h2 class="wp-block-heading">Recent AI Policy Shifts</h2>
<a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46700433/broadcom-stock-is-trending-whats-going-on" rel="noreferrer noopener">Recent developments have</a> reshaped the semiconductor industry's interconnected landscape, influencing valuations.
The U.S. recently paused tech export restrictions to China to avoid disrupting trade talks and to support President Donald Trump's efforts to meet with Chinese President Xi Jinping, according to the Financial Times.
This policy shift aligns with Nvidia's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) move to resume H20 AI chip sales to China, effectively reversing an earlier Trump-era ban. The change could benefit U.S. chipmakers as trade negotiations resume in Stockholm.
The White House fueled industry optimism by launching "Winning the AI Race: America's AI Action Plan," detailing over 90 federal initiatives to strengthen AI leadership, innovation, and infrastructure.
The administration plans to fast-track data centers and chip plant permits, boost workforce training, streamline regulations, and ensure fairness in AI-related contracts.
Meanwhile, Nvidia reportedly ordered 300,000 H20 AI chips from contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), signaling a shift in its production strategy.
Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) also gained ground by capitalizing on AI demand, raising the price of its MI350 chip to $25,000.
Price Action: MRVL stock was trading higher by 7.34% at $82.00 as of last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46717146/united-microelectronics-chief-cautions-currency-trade-policy-could-dampen-gains" target="_blank" rel="noreferrer noopener">United Microelectronics Chief Cautions Currency, Trade Policy Could Dampen Gains</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Tech

MRVL

NVDA

Marvell Stock Rebounds On AI Momentum, New Global Chip Partnership

Cryptocurrency markets are trading down after the Federal Reserve decided to keep the Federal Funds rate unchanged.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$116,074</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,690</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$172.30</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$3.02</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2109</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001241</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction decreased by 9.6% and 20.8%, respectively. Daily active addresses moved higher by 2.5% and 12.7%, respectively.</li>
<li>Coinglass data shows 108,863 traders were liquidated in the past 24 hours for $216.32 million.</li>
<li>The top losers in the past 24 hours include SPX6900, Bonk and Conflux.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46721901/jpmorgan-partners-with-coinbase-to-expand-crypto-access-for-80m-customers">JPMorgan Partners With Coinbase To Expand Crypto Access For 80M Customers</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46720657/turkeys-uber-joins-strategy-tesla-as-bitcoin-treasury-company">&#8216;Turkey&#8217;s Uber&#8217; Joins Strategy, Tesla As Bitcoin Treasury Company</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46729976/300-growth-in-high-inflation-nations-why-stablecoins-are-booming-where-fiat-is-failing">300% Growth In High-Inflation Nations: Why Stablecoins Are Booming Where Fiat Is Failing</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46714238/ethereum-foundation-faces-backlash-for-dumping-100-million-eth-after-saying-believe-in-something">Ethereum Foundation Faces Backlash For &#8216;Dumping&#8217; $100 Million ETH After Saying &#8216;Believe In somETHing&#8217;</a></li>
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46714603/fis-circle-team-up-to-enable-stablecoin-transactions-for-financial-institutions">FIS, Circle Team Up To Enable Stablecoin Transactions For Financial Institutions</a></li>
</ul>
Trader Notes: Crypto trader CrediBULL Crypto suggests Bitcoin may be mirroring a prior consolidation pattern, referencing his signature "GREEN squiggles." He expects few days of tight, sideways chop before a potential breakout or expansion move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Think we may be seeing something similar to the GREEN squiggles that we saw in the quoted tweet below. Maybe a few days of tight chop before expansion&#8230;<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/IwT9yhxi3m">https://t.co/IwT9yhxi3m</a> <a href="https://t.co/bb4kihn6zM">pic.twitter.com/bb4kihn6zM</a>
&mdash; CrediBULL Crypto (@CredibleCrypto) <a href="https://twitter.com/CredibleCrypto/status/1950610174688788590?ref_src=twsrc%5Etfw">July 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ted Pillows <a href="https://x.com/TedPillows/status/1950593480079941684">highlights</a> that Bitcoin has remained range-bound for weeks, even as global liquidity steadily rises. 
He says the lag is temporary, reminiscent of Q2 behavior, and predicts BTC will soon catch up with macro tailwinds, targeting above $135,000 in Q3.
Henry aka LordOfAlts <a href="https://x.com/LordOfAlts/status/1950429488661352960">remains</a> undeterred by short-term volatility, calling the current pullbacks &#8220;noise within a larger bullish structure.&#8221; 
He notes whales are taking profits and Bitcoin is forming a bullish pennant, with recent downside pressure likely meant to trigger liquidations.
He sees a fourth touch near $114,000 as a key long entry, aligning with his long-term "buy the fear, sell the greed" thesis. Henry expects one final &#8220;Oops moment&#8221; before Bitcoin's next parabolic breakout.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46720222/ethereums-rally-driven-by-fresh-inflows-not-a-rotation-out-of-bitcoin-report">Ethereum&#8217;s Rally Driven By Fresh Inflows, Not A Rotation Out Of Bitcoin: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Decline After Federal Reserve Holds Rates

Waste Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) reported better-than-expected earnings for the second quarter, after the <a href="https://www.benzinga.com/quote/WM/earnings">closing bell on Monday.</a>
The company posted quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.89 per share. The company reported quarterly sales of $6.430 billion which beat the analyst consensus estimate of $6.369 billion.
&#8220;As we described at our recent Investor Day, WM is building distinctive platforms to drive competitive differentiation and fuel a powerful, long-term growth engine to create shareholder value. Our second quarter results are a strong demonstration of our progress on all fronts,&#8221; said Jim Fish, WM&#8217;s CEO. &#8220;Our Collection and Disposal business produced robust organic revenue growth and margin expansion, achieving the Company&#8217;s best-ever operating expense margin. We also grew operating EBITDA by double digits in both our Recycling Processing and Sales and WM Renewable Energy segments, as the earnings contributions from investments we have made in our sustainability businesses accelerate. Additionally, we continue to integrate our newest segment, WM Healthcare Solutions, and benefit from the impact of WM&#8217;s culture and operational excellence on customer relationships, cost efficiency, and financial results.&#8221;
Waste Management lowered its FY2025 sales guidance from $25.550 billion-$25.800 billion to $25.275 billion-$25.475 billion.
Waste Management shares fell 0.7% to trade at $233.95 on Wednesday.
These analysts made changes to their price targets on Waste Management following earnings announcement.
<ul class="wp-block-list">
<li>Oppenheimer analyst Noah Kaye maintained Waste Management with an Outperform rating and raised the price target from $260 to $265.</li>
<li>UBS analyst Jon Windham maintained the stock with a Neutral and raised the price target from $260 to $265.</li>
<li>BMO Capital analyst Devin Dodge maintained Waste Management with a Market Perform rating and raised the price target from $245 to $248.</li>
</ul>
Considering buying WM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/wm/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-1024x573.png" alt="" class="wp-image-1007782" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30151311/image-489.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>
Photo via Shutterstock

Waste Management Analysts Increase Their Forecasts After Strong Q2 Earnings

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of <a href="https://www.benzinga.com/markets/earnings/25/07/46692220/merck-ceo-sees-minimal-eu-tariffs-impact-warns-of-gardasil-challenges">successes and setbacks.</a>
Merck reported a mixed second-quarter earnings picture on Tuesday. Adjusted earnings exceeded analyst consensus, but overall sales declined slightly year-over-year and fell short of revenue expectations.
<ul class="wp-block-list">
<li>MRK is consolidating close to its 52-week bottom. <a href="https://www.benzinga.com/quote/MRK" target="_blank" rel="noreferrer noopener">See real-time price here.</a></li>
</ul>
Investors were concerned about a significant drop in Gardasil vaccine sales, even as its blockbuster cancer drug Keytruda continued its strong growth trajectory.
Adjusted earnings per share of $2.13 surpassed <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimates</a> of $2.04, marking a decline from the $2.28 reported in the prior-year period.
Total sales of $15.81 billion, a 2% year-over-year decrease, narrowly missed analysts&#8217; projections of $15.94 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug" rel="noreferrer noopener">Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug</a>
Bank of America (BofA) Securities lowered the price forecast from <a href="https://www.benzinga.com/quote/MRK/analyst-ratings">$99 to $98, with a Buy rating</a>.
BofA says its revenue estimates are about 1% to 2% lower, mainly due to weaker Gardasil sales, though this is partly balanced by stronger Keytruda performance. Merck has said it won&#8217;t be shipping Gardasil to China in 2025, and this delay may continue into 2026. BofA&#8217;s core earnings estimates remain mostly the same.
Analyst Tim Anderson noted during the investor call that the primary focus, surprisingly, wasn&#8217;t on Gardasil, even though its slightly weaker Q2 performance likely caused the stock to drop 8% at the open before recovering to close just 2% lower.
Instead, most of the discussion centered on the company&#8217;s cancer drugs, such as Keytruda, and its cardiovascular and kidney treatments, including Winrevair. Overall, the rest of the business appears to be performing well.
MRK Price Action: Merck &amp; Co shares were down 0.53% at $82.19 at the time of publication on Wednesday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/07/46729590/netflix-hits-records-with-happy-gilmore-2-despite-lower-ratings-than-original-1996-film" target="_blank" rel="noreferrer noopener">Netflix Hits Records With &#8216;Happy Gilmore 2&#8217; Despite Lower Ratings Than Original 1996 Film</a></li>
</ul>
Photo: Shutterstock

Large Cap

Guidance

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

On Wednesday, GE HealthCare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NYSE">GEHC</a>) reported second-quarter 2025 adjusted earnings of $1.06 per share, which beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 92 cents</a>. It was up from $1.00 a year ago.
The company reported sales of $5.01 billion, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46716016/ge-healthcare-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">consensus of $4.96 billion</a>.
Revenues increased 3% on reported and 2% on an organic basis year-over-year. Revenue growth was driven by strength in the U.S. and Europe, the Middle East, and Africa.
Total company book-to-bill was 1.07 times. Total company orders increased 3% organically year-over-year.
The net income margin was 9.7% versus 8.9% for the prior year, which was up 80 basis points (bps) with lower tax and interest expenses.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/05/45662285/nvidia-unveils-foundation-models-for-humanoids-eyes-era-of-robotics-as-ai-spend-accelerates" rel="noreferrer noopener">Nvidia Unveils Foundation Models For Humanoids, Eyes &#8216;Era of Robotics&#8217; As AI Spend Accelerates</a>
Adjusted EBIT margin was 14.6% versus 15.3%, down 80 bps, impacted by tariffs, partially offset by benefits from productivity and volume.
GE HealthCare President and CEO Peter Arduini said, &#8220;We were pleased with solid orders and revenue performance in the second quarter across all segments, reflecting healthy customer investment in capital equipment. We also reported strong earnings performance while leveraging our lean capabilities and demonstrating progress on tariff mitigation&#8230;&#8221;
<h2 class="wp-block-heading">Guidance</h2>
GE HealthCare raises its fiscal 2025 adjusted earnings from $3.90-$4.10 per share to $4.43-$4.63 per share compared to the consensus of $4.07.
The earnings outlook includes approximately 45 cents of tariff impact.
Increased 2025 full-year guidance, reflective of healthy capital investment trends, operational execution, and changes in tariff rates.
Adjusted EBIT margin of 15.2%-15.4%, reflecting a decline of 110 bps to 90 bps versus the 2024 Adjusted EBIT margin of 16.3%; this compares to the previous Adjusted EBIT <a target="_blank" href="https://www.benzinga.com/25/04/45105997/ge-healthcare-q1-earnings-beat-expectations-tariffs-to-impact-2025-profit-outlook" rel="noreferrer noopener">margin guidance of 14.2%-14.4%</a>.
The company forecasts Free cash flow of at least $1.4 billion; this compares to previous Free cash flow guidance of at least $1.2 billion.
Price Action: GEHC stock is down 7.53% at $71.87 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46727882/novo-nordisk-stock-hits-new-52-week-low-amid-profit-warning-what-investors-need-to-know" target="_blank" rel="noreferrer noopener">Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know</a></li>
</ul>
Photo by PixelBiss via Shutterstock

GEHC

GE HealthCare Core Operating Margin Faces Tariffs Heat, Raises Annual Outlook

Press Releases

Catheter Precision, Inc. Announces New Chief Financial Officer

Catheter Precision, Inc.  Announces Initial LockeT Purchase From the University of Tennessee Medical Center

Catheter Precision, Inc.  Announces Definitive Agreement to Acquire PeriKard, LLC

Catheter Precision to Attend the 30th International Atrial Fibrillation Symposium

Catheter Precision, Inc.  Announces The Closing of its Acquisition of PeriKard, LLC

Contracts

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

Catheter Precision, Inc.  Announces Fourth Quarter and Full Year 2024 Update and Financial Results

Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

Comments

Catheter Precision

Catheter Precision (VTAK) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL